Les Tari
Direttore Tecnico/Scientifico/R&S presso CIDARA THERAPEUTICS, INC.
Patrimonio netto: 241 423 $ in data 30/04/2024
Posizioni attive di Les Tari
Società | Posizione | Inizio | Fine |
---|---|---|---|
CIDARA THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/03/2019 | - |
Corporate Officer/Principal | 01/07/2014 | 01/03/2019 |
Storia della carriera di Les Tari
Precedenti posizioni note di Les Tari
Società | Posizione | Inizio | Fine |
---|---|---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/03/2007 | 01/03/2014 |
ActiveSight
ActiveSight Medical DistributorsDistribution Services ActiveSight designed and developed protein portfolio drugs. The company was founded by Ronald V. Swanson and Duncan McRee and was headquartered in San Diego, CA. | Fondatore | 01/01/2003 | 01/01/2007 |
Corporate Officer/Principal | 01/01/2003 | 01/01/2007 | |
Syrrx, Inc.
Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Corporate Officer/Principal | 01/01/2001 | 01/01/2003 |
Formazione di Les Tari
University of Manitoba | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Canada | 2 |
Posizioni
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 2 |
Distribution Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
CIDARA THERAPEUTICS, INC. | Health Technology |
Aziende private | 3 |
---|---|
ActiveSight
ActiveSight Medical DistributorsDistribution Services ActiveSight designed and developed protein portfolio drugs. The company was founded by Ronald V. Swanson and Duncan McRee and was headquartered in San Diego, CA. | Distribution Services |
Syrrx, Inc.
Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Health Technology |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- Les Tari
- Esperienza